Program
BCG Vaccine
Also written as “BCG”, “BCG for Therapeutic Use” and “Bacillus Calmette-Guerin”.
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urinary Bladder Neoplasms · Tuberculosis · Alzheimer Disease · Melanoma, led by 10 companies.
Drug pageBCG Vaccine: every studyMany companies study it; this page follows only the 16 they lead. All 103 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chongqing Zhifei Biological Productsits history only | 41 open or running | phase 3since Mar 14, 2016 | Mar 5, 2015 | Apr 30, 2028phase 3 · NCT06747455 |
| ImmunityBioits history only | 32 open or running | phase 3since Apr 20, 2026 | May 13, 2014 | Nov 2026phase 2 · NCT06829823 |
| Chengdu CoenBiotechits history only | 21 open or running | phase 3since Jan 28, 2024 | Jan 28, 2024 | none ahead |
| AstraZenecaits history only | 11 open or running | phase 3since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| Heat Biologicsits history only | 10 open or running | phase 2since Dec 5, 2013 | Dec 5, 2013 | none ahead |
| Laboratorio Pablo Cassará S.R.L.its history only | 10 open or running | phase 3since Nov 14, 2012 | Nov 14, 2012 | none ahead |
| Merckits history only | 11 open or running | phase 2since Feb 4, 2025 | Feb 4, 2025 | Sep 3, 2031phase 2 · NCT06833073 |
| Mindful Diagnostics and Therapeuticsits history only | 10 open or running | phase 2since Jun 24, 2020 | Jun 24, 2020 | none ahead |
| Pfizerits history only | 11 open or running | phase 3since Nov 13, 2019 | Nov 13, 2019 | none ahead |
| Verity Pharmaceuticalsits history only | 11 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | Feb 2029phase 3 · NCT05037279 |
Also a collaborator on its studies: Moderna, Parexel and Proswell Medical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Nov 14, 2012.
- May 13, 2014ImmunityBio’s first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to ImmunityBioImmunityBio · NCT02138734 · 369 enrolled · United States, India, South Africa
- Mar 5, 2015Chongqing Zhifei Biological Products’ first study: phase 2 study in TuberculosisNew to Chongqing Zhifei Biological ProductsChongqing Zhifei Biological Products · NCT02389322 · 1,044 enrolled · China
- Mar 14, 2016Phase 3 study in TuberculosisChongqing Zhifei Biological Products · NCT02795260 · 1,802 enrolled
- Nov 13, 2019Pfizer’s first study: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNew to PfizerPfizer · NCT04165317 · 1,068 enrolled · United States, Australia, Belgium and more
- Jun 24, 2020Mindful Diagnostics and Therapeutics’ first study: phase 2 study in Alzheimer DiseaseNew to Mindful Diagnostics and TherapeuticsMindful Diagnostics and Therapeutics · NCT04449926 · 49 enrolled · United States
- Jul 28, 2021Verity Pharmaceuticals’ first study: phase 3 study in Urinary Bladder NeoplasmsNew to Verity PharmaceuticalsVerity Pharmaceuticals · NCT05037279 · 540 planned · Canada
- Jul 5, 2023AstraZeneca’s first study: phase 3 study in Non-Muscle Invasive Bladder NeoplasmsNew to AstraZenecaAstraZeneca · NCT05943106 · 100 enrolled · United States
- Oct 13, 2023Phase 1 study in Non-muscular Invasive Bladder CancerChongqing Zhifei Biological Products · NCT06100653 · 10 enrolled · China
- Jan 28, 2024Chengdu CoenBiotech’s first study: phase 1 study in Urinary Bladder NeoplasmsNew to Chengdu CoenBiotechChengdu CoenBiotech · NCT06350838 · 10 enrolled · China
- Jan 28, 2024Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsChengdu CoenBiotech · NCT06241755 · 412 planned · China
- Dec 18, 2024Phase 3 study in Urinary Bladder NeoplasmsChongqing Zhifei Biological Products · NCT06747455 · 439 enrolled · China
- Feb 4, 2025Merck’s first study: phase 2 study in Urinary Bladder NeoplasmsNew to MerckMerck · NCT06833073 · 308 planned · United States, Argentina, Australia and more
- Feb 5, 2025Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsImmunityBio · NCT06829823 · 20 planned
- Apr 20, 2026Phase 3 study in Non-Muscle Invasive Bladder NeoplasmsPhase 3 reachedImmunityBio · NCT07551544
Ahead
- Nov 2026Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsImmunityBio · NCT06829823
- Apr 30, 2028Primary completion: phase 3 study in Urinary Bladder NeoplasmsChongqing Zhifei Biological Products · NCT06747455
- Feb 2029Primary completion: phase 3 study in Urinary Bladder NeoplasmsVerity Pharmaceuticals · NCT05037279
- Sep 3, 2031Primary completion: phase 2 study in Urinary Bladder NeoplasmsMerck · NCT06833073
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities”NCIt, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07551544Non-Muscle Invasive Bladder Neoplasms | 3 | Withdrawn | ImmunityBio | May 2032 | 0 |
| NCT06829823Non-Muscle Invasive Bladder Neoplasms | 2 | Not yet recruiting | ImmunityBio | Nov 2026 | 20 |
| NCT06833073Urinary Bladder Neoplasms · United States, Argentina, Australia and more | 2 | Recruiting | Merck | Sep 3, 2031 | 308 |
| NCT06747455Urinary Bladder Neoplasms · China | 3 | Active, not recruiting | Chongqing Zhifei Biological Products | Apr 30, 2028 | 439 |
| NCT06350838Urinary Bladder Neoplasms · China | 1 | Completed | Chengdu CoenBiotech | Feb 13, 2023 | 10 |
| NCT06241755Non-Muscle Invasive Bladder Neoplasms · China | 3 | Recruiting | Chengdu CoenBiotech | Sep 1, 2025 | 412 |
| NCT06100653Non-muscular Invasive Bladder Cancer · China | 1 | Completed | Chongqing Zhifei Biological Products | Jan 1, 2025 | 10 |
| NCT05943106Non-Muscle Invasive Bladder Neoplasms · United States | 3 | Active, not recruiting | AstraZeneca | Jun 16, 2025 | 100 |
| NCT05037279Urinary Bladder Neoplasms · Canada | 3 | Recruiting | Verity Pharmaceuticals | Feb 2029 | 540 |
| NCT04449926Alzheimer Disease · United States | 2 | Completed | Mindful Diagnostics and Therapeutics | Dec 4, 2021 | 49 |
| NCT04165317Non-Muscle Invasive Bladder Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | Pfizer | Dec 2, 2024 | 1,068 |
| NCT02795260Tuberculosis | 3 | Completed | Chongqing Zhifei Biological Products | Oct 2016 | 1,802 |
| NCT02389322Tuberculosis · China | 2 | Completed | Chongqing Zhifei Biological Products | Jul 2015 | 1,044 |
| NCT02138734Non-Muscle Invasive Bladder Neoplasms · United States, India, South Africa | 2 | Active, not recruiting | ImmunityBio | Sep 30, 2026 | 369 |
| NCT02010203Urinary Bladder Neoplasms · United States | 2 | Terminated | Heat Biologics | Dec 2017 | 104 |
| NCT01729663Melanoma · Argentina | 3 | UNKNOWN | Laboratorio Pablo Cassará S.R.L. | Dec 2018 | 108 |
How it is read
Names in the registry
- “BCG”, 4 entries
- “BCG for Therapeutic Use”, 4 entries
- “Bacillus Calmette-Guerin”, 1 entry
- “BCG (50 mg) plus ANKTIVA (400 µg)”, 1 entry
- “BCG (50 mg)”, 1 entry
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 7 studies
- Urinary Bladder Neoplasms, 5 studies
- Tuberculosis, 2 studies
- Alzheimer Disease, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.